Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

1.000 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.000
Bid (Size) 0.9800 (1)
Ask (Size) 1.100 (4)
Prev. Close 1.000
Today's Range 1.000 - 1.000
52wk Range 0.9452 - 4.440
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
Via ACCESS Newswire
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
Via ACCESS Newswire

Performance

YTD
-56.5%
-56.5%
1 Month
-28.1%
-28.1%
3 Month
-33.8%
-33.8%
6 Month
-52.2%
-52.2%
1 Year
-65.8%
-65.8%

More News

Read More
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill
Top stock movements in today's session.
Via Chartmill
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Via ACCESS Newswire
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Via ACCESS Newswire
Crude Oil Edges Higher; Phillips 66 Posts Wider-Than-Expected Loss
Via Benzinga
Exposures Fossil Fuels
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
These stocks that are showing activity before the opening bell on Friday.
Via Chartmill
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Via ACCESS Newswire
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Via ACCESS Newswire
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
Via ACCESS Newswire
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Via ACCESS Newswire
Dow Falls 200 Points; Alphabet Posts Upbeat Q1 Results
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
Via ACCESS Newswire
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
Via ACCESS Newswire
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
Via ACCESSWIRE
Lexaria Bioscience Earnings Analysis: Q1 Recap
Via Benzinga
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Via ACCESSWIRE
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Via ACCESS Newswire
Lexaria's Human GLP-1 Study #5 Begins Dosing
Via ACCESS Newswire
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
Via ACCESS Newswire
Lexaria Releases Annual Letter from the CEO
Via ACCESS Newswire
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Via ACCESSWIRE

Frequently Asked Questions

Is Lexaria Bioscience Corp. - Common Stock publicly traded?
Yes, Lexaria Bioscience Corp. - Common Stock is publicly traded.
What exchange does Lexaria Bioscience Corp. - Common Stock trade on?
Lexaria Bioscience Corp. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lexaria Bioscience Corp. - Common Stock?
The ticker symbol for Lexaria Bioscience Corp. - Common Stock is LEXX on the Nasdaq Stock Market
What is the current price of Lexaria Bioscience Corp. - Common Stock?
The current price of Lexaria Bioscience Corp. - Common Stock is 1.000
When was Lexaria Bioscience Corp. - Common Stock last traded?
The last trade of Lexaria Bioscience Corp. - Common Stock was at 05/19/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.